2017-10-22 16:00Financial Performance - Net profit attributable to shareholders was RMB 1,485,651 thousand, representing a 40.63% increase year-on-year[10]. - Operating revenue for the first nine months was RMB 15,966,932 thousand, up 2.72% from the same period last year[10]. - Basic earnings per share increased by 14.97% to RMB 0.914[10]. - The company reported a net profit of RMB 1,444,976 thousand after deducting non-recurring gains and losses, a 65.97% increase year-on-year[10]. - Total operating revenue for Q3 2017 reached ¥4,851,593,362.61, an increase of 3.52% compared to ¥4,686,415,546.92 in Q3 2016[30]. - Operating profit for Q3 2017 was ¥387,845,524.63, a significant increase of 77.4% from ¥218,891,669.67 in Q3 2016[31]. - Net profit attributable to shareholders for Q3 2017 was ¥327,511,292.05, up 45.9% from ¥224,615,728.31 in Q3 2016[31]. - Total profit for the first nine months of 2017 was ¥1,799,729,351.23, up from ¥1,339,460,686.68 in the same period of 2016, representing a growth of 34.4%[31]. - The total profit for Q3 2017 was ¥171,809,703.62, an increase of 21.5% from ¥141,412,923.54 in Q3 2016[36]. Assets and Liabilities - Total assets reached RMB 27,025,105 thousand, an increase of 4.36% compared to the end of the previous year[10]. - The company's cash and cash equivalents decreased to CNY 6.52 billion from CNY 8.36 billion, a decline of approximately 22%[25]. - Current liabilities amounted to CNY 7.48 billion, slightly up from CNY 7.42 billion, indicating a marginal increase of 0.8%[23]. - The total liabilities stood at CNY 8.29 billion, a slight increase from CNY 8.24 billion, representing a growth of about 0.6%[23]. - The company's retained earnings increased to CNY 5.81 billion from CNY 4.78 billion, a growth of approximately 21.5%[23]. - Total liabilities decreased by 38.36% in prepayments to RMB 957.16 million, reflecting a reduction in advance payments to distributors[16]. Cash Flow - Net cash flow from operating activities was RMB 1,811,423 thousand, down 26.61% compared to the previous year[10]. - The cash flow from operating activities for the first nine months was ¥12,296,202,127.25, down from ¥13,423,052,755.44 in the same period last year[39]. - Cash outflow from investing activities reached ¥3,222,335,217.43, significantly higher than ¥774,702,100.55 in the previous year, resulting in a net cash flow from investing activities of (¥1,975,669,656.85)[43]. - Cash flow from financing activities showed a net outflow of (¥487,820,897.76), compared to a net inflow of ¥7,685,293,811.25 in the same period last year[44]. - The ending balance of cash and cash equivalents was ¥6,484,298,622.14, down from ¥9,248,751,548.84 at the end of the previous year[44]. Shareholder Information - The number of shareholders as of September 30, 2017, was 63,704, with 63,677 holding A shares[11]. - Guangzhou Pharmaceutical Group Co., Ltd. held 45.04% of the shares, making it the largest shareholder[13]. Government Support and Investments - The company received government subsidies amounting to RMB 92,926 thousand during the first nine months[11]. - The company established two new subsidiaries in August 2017, each with a registered capital of RMB 10 million, enhancing its market presence[18]. - The company received investment income of ¥459,219,469.86, a significant increase from ¥126,550,345.05 in the previous year[43]. Other Financial Metrics - The weighted average return on equity decreased by 2.51 percentage points to 8.21%[10]. - Financial expenses increased by 104.89% to a loss of RMB 112.70 million, indicating a need for improved capital management[16]. - The company's other payables rose by 32.58% to RMB 3.01 billion, primarily due to increased accrued expenses[16]. - The company recorded an asset impairment loss of RMB 3.23 million, a 276.63% increase year-on-year, indicating potential challenges in asset valuation[16]. - The company has reported a significant increase in investment income, reaching ¥38,319,325.34 in Q3 2017, compared to ¥29,414,666.39 in Q3 2016, indicating a growth of 30.5%[31].